Encouraging Outcomes of CAR T-cell Therapy for Leukemia and Lymphoma in Sweden
Swedish research reports improved survival rates and fewer side effects in leukemia and lymphoma patients receiving CAR T-cell therapy, marking a significant advancement in cancer immunotherapy.
Recent advancements in immunotherapy have shown promising results with CAR T-cell treatment for patients suffering from certain blood cancers. A comprehensive analysis conducted within the Swedish SWECARNET network highlights that patients with aggressive B-cell lymphoma (ABCL) treated with CAR T-cell therapy exhibit improved survival rates and experience fewer severe side effects than previously recorded in early trials. The study, published in the journal Leukemia, encompasses data from 93 adult patients treated between 2019 and 2024.
The findings reveal that approximately 66% of these patients achieved complete remission, with no detectable cancer within 30 days post-treatment. Moreover, over half of these patients, about 53%, remained in remission one year after therapy. Interestingly, the study found no significant difference in treatment outcomes between older and younger patients, indicating that age may not be a limiting factor for this advanced therapy.
Since Uppsala University Hospital pioneered the first European clinical trial of CAR T-cell therapy for B-cell lymphoma, Sweden has become a leader in this innovative treatment approach. The advancements are attributed not only to improvements in the therapy itself but also to better patient selection and management of side effects, marking an important step toward refining cancer immunotherapy.
Overall, CAR T-cell therapy offers a beacon of hope for patients with treatment-resistant blood cancers, demonstrating enhanced efficacy and safety profiles. Ongoing research and clinical experience continue to shape its role in standard cancer care, providing new opportunities for successful treatment of previously incurable hematologic malignancies.
Source: [https://medicalxpress.com/news/2025-05-results-car-cell-therapy-leukemia.html]
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Biomedical Engineering Students Innovate to Address Safety Challenges in Sports and Daily Life
Biomedical engineering students at the University of Cincinnati are developing innovative solutions to prevent and repair injuries in sports and everyday life, focusing on concussion prevention, safer gear, and neonatal safety.
New Study Reveals 9% of Young US Workers Use Alcohol and Drugs at Work
A new study finds nearly 9% of young US workers consume alcohol or drugs during work hours, highlighting occupational safety concerns and the need for comprehensive policies and support services.
Recognizing the Signs of Peripheral Artery Disease (PAD) in Your Legs
Learn how to identify the warning signs of peripheral artery disease (PAD), a serious condition affecting blood flow to the legs. Early detection and lifestyle changes are essential to prevent severe complications like ulcers and limb loss.
The Promising Role of Vaccines in Combating Dementia
Emerging research indicates that vaccines, particularly for shingles, may significantly reduce the risk of dementia. This groundbreaking study suggests a new therapeutic avenue for neurodegenerative diseases, emphasizing the broader potential of vaccines beyond infection prevention.